UBS Group Begins Coverage on 10x Genomics (NASDAQ:TXG)
UBS Group Begins Coverage on 10x Genomics (NASDAQ:TXG)
UBS Group started coverage on shares of 10x Genomics (NASDAQ:TXG – Get Rating) in a research report released on Thursday, The Fly reports. The brokerage issued a neutral rating and a $50.00 price target on the stock.
据The Fly报道，瑞银集团在周四发布的一份研究报告中开始对10倍基因组(纳斯达克：TXG-GET评级)的股票进行报道。该经纪公司对该股发布了中性评级和50.00美元的目标价。
Several other analysts have also commented on TXG. The Goldman Sachs Group dropped their price target on shares of 10x Genomics from $35.00 to $25.00 and set a sell rating on the stock in a research report on Thursday, October 13th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of 10x Genomics in a research note on Tuesday, December 13th. They set a buy rating and a $50.00 target price on the stock. Morgan Stanley lowered their target price on shares of 10x Genomics from $70.00 to $64.00 and set an overweight rating on the stock in a research note on Friday, November 4th. Finally, JPMorgan Chase & Co. lowered their target price on shares of 10x Genomics from $65.00 to $55.00 in a research note on Thursday, November 3rd. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of Hold and an average target price of $50.90.
其他几位分析师也对TXG发表了评论。10月13日，高盛夫妇在一份研究报告中将10x基因组公司的股票目标价从35.00美元下调至25.00美元，并对该股设定了卖出评级。德意志银行Aktiengesellschaft在12月13日(星期二)的一份研究报告中假设了10倍基因组公司的股票。他们为该股设定了买入评级和50.00美元的目标价。摩根士丹利在11月4日(周五)的一份研究报告中将10倍基因的目标价从70美元下调至64美元，并对该股设定了增持评级。最后，摩根大通公司在11月3日星期四的一份研究报告中将10x基因组公司股票的目标价从65.00美元下调至55.00美元。两名股票研究分析师将该股评级为卖出，两名分析师给出了持有评级，六名分析师给出了该公司的买入评级。根据MarketBeat.com的数据，该股的普遍评级为持有，平均目标价为50.90美元。
10x Genomics Stock Down 3.6 %
10倍基因组学股票下跌3.6%
Shares of TXG traded down $1.79 during trading hours on Thursday, reaching $47.93. 111,934 shares of the company traded hands, compared to its average volume of 1,146,258. 10x Genomics has a 12-month low of $23.81 and a 12-month high of $99.14. The stock's fifty day moving average price is $39.36 and its 200 day moving average price is $35.90.
在周四的交易时段，TXG的股价下跌了1.79美元，达到47.93美元。该公司有111,934股易手，而平均成交量为1,146,258股。10倍基因组学的12个月低点为23.81美元，12个月高位为99.14美元。该股的50日移动均线价格为39.36美元，200日移动均线价格为35.90美元。
Insiders Place Their Bets
内部人士下注
In other news, insider Benjamin J. Hindson sold 2,361 shares of the firm's stock in a transaction on Tuesday, November 22nd. The stock was sold at an average price of $34.07, for a total value of $80,439.27. Following the completion of the transaction, the insider now owns 217,713 shares in the company, valued at $7,417,481.91. The sale was disclosed in a document filed with the SEC, which is available at this link. In other news, insider Benjamin J. Hindson sold 2,361 shares of 10x Genomics stock in a transaction dated Tuesday, November 22nd. The stock was sold at an average price of $34.07, for a total value of $80,439.27. Following the transaction, the insider now directly owns 217,713 shares of the company's stock, valued at approximately $7,417,481.91. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Justin J. Mcanear sold 1,626 shares of 10x Genomics stock in a transaction that occurred on Tuesday, November 22nd. The stock was sold at an average price of $34.07, for a total value of $55,397.82. Following the sale, the chief financial officer now owns 76,764 shares in the company, valued at $2,615,349.48. The disclosure for this sale can be found here. Over the last quarter, insiders sold 6,663 shares of company stock worth $227,008. 11.08% of the stock is owned by corporate insiders.
另一则消息是，内部人士本杰明·J·辛德森在11月22日星期二的一次交易中出售了2361股该公司股票。这只股票的平均售价为34.07美元，总价值为80439.27美元。交易完成后，这位内部人士现在拥有该公司217,713股股票，价值7,417,481.91美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，该文件可在这个环节。在其他新闻方面，内部人士本杰明·J·辛德森在11月22日星期二的交易中出售了2361股10倍基因组公司的股票。这只股票的平均售价为34.07美元，总价值为80439.27美元。交易完成后，这位内部人士现在直接持有该公司217,713股股票，价值约7,417,481.91美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，该文件可通过美国证券交易委员会网站。此外，首席财务官贾斯汀·J·曼坎尔在11月22日(星期二)的一笔交易中出售了1,626股10倍基因组公司的股票。这只股票的平均售价为34.07美元，总价值为55397.82美元。出售后，首席财务官现在拥有该公司76,764股，价值2,615,349.48美元。关于这次销售的披露可以找到这里。在上个季度，内部人士出售了6663股公司股票，价值227,008美元。11.08%的股份由企业内部人士持有。
Institutional Investors Weigh In On 10x Genomics
机构投资者参与10倍基因组学
A number of institutional investors and hedge funds have recently modified their holdings of TXG. Wipfli Financial Advisors LLC acquired a new position in 10x Genomics during the third quarter valued at $26,000. First Horizon Advisors Inc. boosted its stake in 10x Genomics by 14,780.0% during the 2nd quarter. First Horizon Advisors Inc. now owns 744 shares of the company's stock valued at $33,000 after purchasing an additional 739 shares during the period. Atlas Capital Advisors LLC boosted its stake in 10x Genomics by 45.5% during the 3rd quarter. Atlas Capital Advisors LLC now owns 1,360 shares of the company's stock valued at $39,000 after purchasing an additional 425 shares during the period. CWM LLC raised its holdings in 10x Genomics by 48.9% in the 4th quarter. CWM LLC now owns 1,185 shares of the company's stock valued at $43,000 after acquiring an additional 389 shares in the last quarter. Finally, Rockefeller Capital Management L.P. raised its holdings in 10x Genomics by 95.2% in the 3rd quarter. Rockefeller Capital Management L.P. now owns 2,875 shares of the company's stock valued at $81,000 after acquiring an additional 1,402 shares in the last quarter. 74.34% of the stock is owned by institutional investors and hedge funds.
一些机构投资者和对冲基金最近调整了对TXG的持股。Wipfli Financial Advisors LLC在第三季度收购了10x基因组公司的一个新头寸，价值2.6万美元。第一地平线顾问公司(First Horizon Advisors Inc.)在第二季度将其在10倍基因组公司的持股增加了14,780.0%。First Horizon Advisors Inc.在此期间又购买了739股，现在持有744股该公司股票，价值3.3万美元。Atlas Capital Advisors LLC在第三季度将其在10倍基因组公司的持股增加了45.5%。Atlas Capital Advisors LLC在此期间又购买了425股，现在拥有1360股该公司的股票，价值3.9万美元。Cwm LLC在第四季度增持了10x基因组学48.9%的股份。Cwm LLC在上个季度增持了389股后，现在拥有1185股该公司股票，价值4.3万美元。最后，洛克菲勒资本管理公司(Rockefeller Capital Management L.P.)在第三季度将其在10倍基因组公司的持股增加了95.2%。洛克菲勒资本管理公司(Rockefeller Capital Management L.P.)在上个季度增持了1,402股股票后，现在持有该公司2,875股股票，价值81,000美元。74.34%的股票由机构投资者和对冲基金持有。
10x Genomics Company Profile
10倍基因组学公司简介
(Get Rating)
(获取评级)
10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products.
10x基因公司是一家生命科学技术公司，在北美、欧洲、中东、非洲、中国和亚太地区开发和销售用于分析生物系统的仪器、消耗品和软件。本公司提供铬及铬连接仪器、微流控芯片、载玻片、试剂等耗材产品。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on 10x Genomics (TXG)
- Ford Stock Going Forward After Big Earnings Flop
- Insiders And Institutions Buy Wolverine Worldwide
- Nvidia Rallies As Investors Bullish On Chipmaker's AI Business
- Bright Green Corporation Future May be Getting Brighter
- Microsoft Fast Integrating AI Into Enterprise & Healthcare Suites
- 免费获取StockNews.com关于10x基因组学(TXG)的研究报告
- 福特股票在盈利大幅下滑后继续前进
- 内部人士和机构收购金刚狼全球
- 英伟达股价上涨，投资者看好芯片制造商的人工智能业务
- 光明绿色公司的未来可能变得更加光明
- 微软将人工智能快速集成到企业和医疗保健套件中
Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.
获得10倍基因组学日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对10x基因组学和相关公司的最新新闻和分析师评级的每日简明摘要。